<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: Asia Major Or Asia Minor? Looking To China &#038; India</title>
	<atom:link href="http://www.pharmalot.com/2008/06/asia-major-or-asia-minor-looking-to-china-india/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/06/asia-major-or-asia-minor-looking-to-china-india/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 20:56:49 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: CMC guy</title>
		<link>http://www.pharmalot.com/2008/06/asia-major-or-asia-minor-looking-to-china-india/#comment-359702</link>
		<dc:creator>CMC guy</dc:creator>
		<pubDate>Thu, 12 Jun 2008 18:34:46 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/?p=14085#comment-359702</guid>
		<description>I agree that this is an increasing trend largely based on economics for conducting R&#38;D (hire 5-10 PhDs vs 1 in US) and that Pharma is more and more operating satellites that provide experience base. Many US/EU trained people are now returning to start-up their own or join the growth in research areas, unlike in past.  I also hear clinical studies are growing in these regions so can have more complete spectrum of R&#38;D.  It is true major shift in quality and ethics will be required.

There has been plenty of "theft" of IP in the past in these countries with governments looking other way (or perhaps participating).  I look forward to when US can use Compulsory Licensing to acquire drugs developed in India/China.</description>
		<content:encoded><![CDATA[<p>I agree that this is an increasing trend largely based on economics for conducting R&amp;D (hire 5-10 PhDs vs 1 in US) and that Pharma is more and more operating satellites that provide experience base. Many US/EU trained people are now returning to start-up their own or join the growth in research areas, unlike in past.  I also hear clinical studies are growing in these regions so can have more complete spectrum of R&amp;D.  It is true major shift in quality and ethics will be required.</p>
<p>There has been plenty of &#8220;theft&#8221; of IP in the past in these countries with governments looking other way (or perhaps participating).  I look forward to when US can use Compulsory Licensing to acquire drugs developed in India/China.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.150 seconds -->

